Last reviewed · How we verify

ACEI/DIU — Competitive Intelligence Brief

ACEI/DIU (ACEI/DIU) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor/Diuretic combination. Area: Cardiovascular.

marketed ACE inhibitor/Diuretic combination Angiotensin-converting enzyme (ACE) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ACEI/DIU (ACEI/DIU) — Shanghai Jiao Tong University School of Medicine. ACEI/DIU is a combination drug that inhibits angiotensin-converting enzyme while providing diuretic activity to reduce blood pressure.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ACEI/DIU TARGET ACEI/DIU Shanghai Jiao Tong University School of Medicine marketed ACE inhibitor/Diuretic combination Angiotensin-converting enzyme (ACE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor/Diuretic combination class)

  1. Shanghai Jiao Tong University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ACEI/DIU — Competitive Intelligence Brief. https://druglandscape.com/ci/acei-diu. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: